hR3 modification with DOTA-NHS. 90Y labeling and biodistribution

Main Article Content

Dianelys Ondarse Álvarez
Rene Leyva Montaña
Minely Zamora Barrabí

Abstract

The conjugation, characterization and biodistribution of -DOTA-hR3 radioimmunoconjugate are reported in this work. DOTA was used as bifunctional chelating agent. Molar ratios 320:1, 160:1 and 88:1 DOTA/monoclonal antibody hR3 were studied in order to evaluate their influence on the integrity of conjugate and labeling effi ciency. In vivo stability of -DOTA-hR3 radioimmunoconjugates was determined in healthy Wistar rats at 4, 24 and 48 h after the injection. Stability studies performed by means of DTPA challenge showed that the compound is stable in a wide period of time (up to 216 h). In vivo stability studies, based on the bone uptake, showed that the radiometal release from the radioimmunoconjugate is not signifi cant in the first 48 hours.

Article Details

How to Cite
Ondarse Álvarez, D., Leyva Montaña, R., & Zamora Barrabí, M. (1). hR3 modification with DOTA-NHS. 90Y labeling and biodistribution. Nucleus, (49). Retrieved from http://nucleus.cubaenergia.cu/index.php/nucleus/article/view/547
Section
Ciencias Nucleares

References

1. LIU S, EDWARDS DS. Bifunctional chelator for therapeutic lanthanide radiopharmaceutical. Bioconjugate Chem. 2001; 12(1): 7-34.
2. ILLIDGE TM, BROCK S. Radioinmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. Curr. Pharm. Res. 2000; 6(14): 1399-1418.
3. VRIESENDORP HM, QUADRI SM, BORCHARD PE. Tumor therapy with radiolabeled antibodies: optimization of therapy. BioDrugs. 1998; 10(4): 275-293.
4. POTAMIANOS S, VARVARIGOU AD, ARCHIMANDRITIS SC. Radioimmunoscintigraphy and radioimmunotherapy in cancer: principles and applications. Anticancer Res. 2000; 20(2A): 925–948.
5. WUN T, KWON DS, TUSCANO JM. Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgekin’s lymphoma. BioDrugs. 2001; 15(3): 151-162.
6. WITZIG TE. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgekin’s lymphoma. Semin. Oncol. 2000; 27 (6 suppl 12)1: 74-78.
7. HIDER RC, HALL AD. Iron chelating agents medicine. The application of bidentate hydroxypyridin-4-ones. In: Perspectives Bioinorganic Chemistry. JAI Press, 1991. vol. 1. p. 209-253.
8. DADACHOVA E, CHAPPELL LL, BRECHBIEL MW. Spectrophotometric method for determination of bifuncional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med and Biology. 1999; 26(8): 977-982.
9. PIPPIN CG, PARKER TA, MCMURRY TJ, BRECHBIEL MW. Spectrophotometric method for the determination of a bifuncional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem. 1992; 3(4): 342-345.
10. LEWIS MR, KAO JY, ANDERSON ALJ, et. al. An improved method for conjugating monoclonal antibodies with NHydroxysulfosuccinimidyl DOTA. Bioconjug Chem. 2001; 12(2): 320-324.
11. BRADFORD MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248.
12. LIU S, et. al. Comparison of Yttrium and indium complexes of DOTA-BA and DOTA-MBA: Models for 90Y- and 111Inlabelled DOTA- biomolecule conjugates. Bioconjug Chem. 2002. 13(4): 902-913.
13. BECKFORD VERA DR, XIQUES CASTILLO A, LEYVA MONTAÑA R, et. al. Nuevo radioinmunoconjugado 90Y-DOTA- hR3. Síntesis y radiomarcaje. Nucleus. 2007; (41): 3-8.
14. GRIFFITHS GL, GOVINDAN SV, SHARKEY RM, et. al. 90Y-DOTA-hLL2: An agent for radioimmunotherapy of non- Hodgkin’s lymphoma. J. Nucl. Med. 2003; 44(1): 77-84.
15. HANCOCK RD, MARTELL AE, MOTEKAITIS RJ. Factors affecting stabilities of chelate, macrocyclic and macrobicyclic complexes in solution. Coord. Chem. Rev. 1994; 133: 39-65.
16. MORALES AA, NUÑEZ G, PEREZ N, et. al. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: Additives, biodistribution and stability. Nucl. Med. & Biol. 1999; 26(6): 717-723.
17. IZNAGA N, MORALES A, DUCONGÉ J, et. al. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats. Nucl. Med. & Biol. 1998; 25(1): 17- 23.

Most read articles by the same author(s)